A Phase 3, Open-label, Randomized, Controlled Trial of Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukaemia
Latest Information Update: 23 Sep 2026
At a glance
- Drugs Blinatumomab (Primary) ; Blinatumomab
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms AUDAX
- Sponsors Amgen
Most Recent Events
- 15 Sep 2026 Planned primary completion date changed from 10 May 2030 to 30 Dec 2031.
- 15 Sep 2026 Planned initiation date changed from 11 Jun 2026 to 30 Jun 2028.
- 13 Sep 2026 Planned End Date changed from 9 Aug 2033 to 29 Aug 2035.